News

Empty gabapentin capsules spur recall


 

References

Following the discovery of capsules found to be empty, Aurobindo Pharma USA has initiated a recall of the epilepsy treatment gabapentin, the company announced Nov. 21.

The company is voluntarily recalling lot GESB14011-A of 100-count bottles of 300 mg gabapentin, which have an expiration date of December 2015. The product also is used to manage postherpetic neuralgia.

The Food and Drug Administration noted that the empty capsules could result in missed doses, potentially resulting in no effect, short-term efficacy reduction, short-term withdrawal effect, or status epilepticus that could be life threatening.

gtwachtman@frontlinemedcom.com

Recommended Reading

FDA: Naproxen may pose lower CV risk
MDedge Dermatology
NSAID makers argue against new warnings on CV risks
MDedge Dermatology
No new cardiovascular warnings needed for NSAIDs say FDA advisers
MDedge Dermatology
Group issues recommendations for genetic susceptibility testing for carbamazepine skin reactions
MDedge Dermatology
Two definitions of Gulf War illness recommended
MDedge Dermatology
NSAID use linked to reduced risk for second nonmelanoma skin cancer
MDedge Dermatology
Opioid prescribing varies widely across the country
MDedge Dermatology
VIDEO: Dr. Fauci: What you need to know about chikungunya
MDedge Dermatology
Chikungunya vaccine safe, immunogenic in phase I trial
MDedge Dermatology
Psoriatic arthritis patients often changed or stopped treatment
MDedge Dermatology